# AML96 - Risk-Adapted and Randomized Postremission-Therapy for Adult Acute Myeloid Leukemia Patients

> **NCT00180115** · PHASE4 · COMPLETED · sponsor: **Technische Universität Dresden** · enrollment: 400 (—)

## Conditions studied

- Leukemia, Nonlymphoblastic, Acute

## Interventions

- **DRUG:** Cytarabine Dosage

## Key facts

- **NCT ID:** NCT00180115
- **Lead sponsor:** Technische Universität Dresden
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 1996-02
- **Primary completion:** —
- **Final completion:** 2008-11
- **Target enrollment:** 400 (—)
- **Last updated:** 2007-07-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00180115

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00180115, "AML96 - Risk-Adapted and Randomized Postremission-Therapy for Adult Acute Myeloid Leukemia Patients". Retrieved via AI Analytics 2026-07-11 from https://api.ai-analytics.org/clinical/NCT00180115. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*